Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-04-27 English
Mesoblast Completes Private Placement 2 pages 166.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a private placement by Mesoblast Limited, detailing the amount raised, use of proceeds, and company background. It does not contain financial statements, detailed financial analysis, or regulatory filings. The focus is on fundraising activity and capital raising. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report or certification.
2023-04-25 English
Proposed issue of securities - MSB 5 pages 27.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Mesoblast Limited regarding a proposed issue of securities, specifically a placement of 77,083,607 ordinary fully paid shares. It includes details such as the issue price, proposed issue date, regulatory compliance with ASX Listing Rules, and fees related to the issue. The document is structured as an official announcement to the stock exchange about a capital raising event. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits the category of a Capital/Financing Update (CAP). The document length is 5879 characters, which is sufficient for a detailed announcement but not a full financial report.
2023-04-25 English
Reinstatement to Official Quotation 1 page 89.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to quotation of Mesoblast Limited's securities following a private placement announcement. It is brief (605 characters) and does not contain financial statements or detailed financial data. It is an announcement related to capital market activity but does not provide detailed financing information itself. Given the short length and nature as a market announcement, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a detailed Capital/Financing Update (CAP).
2023-04-25 English
Voluntary Suspension 2 pages 289.5KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a voluntary suspension of trading of its securities pending a private placement announcement. It references ASX Listing Rule 17.2 and is a formal request for suspension to allow time to complete a private placement. The document does not contain financial statements, earnings data, or detailed report content. It is an announcement related to capital raising activities but does not itself provide financing details or results. Given the nature of the content, it fits best under Capital/Financing Update (CAP) as it concerns a private placement and suspension related to financing activities.
2023-04-23 English
Pause in Trading 1 page 111.0KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (343 characters) and does not contain any financial data, report content, or detailed information. It is an official regulatory announcement related to trading status, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.